New hope for Crohn's: experimental drug targets gut inflammation

NCT ID NCT05910528

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Participants receive either the drug or a placebo, and researchers monitor side effects and healing of the gut lining.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHNS DISEASE

Contacts and locations

Locations

AZ Delta

Roeselare, 8800, Belgium
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
CHRU de Nancy Brabois

Vandœuvre-lès-Nancy, 54500, France
CHU de Nantes

Nantes, 44093, France
Clinical Research Institute of Michigan

Chesterfield, Michigan, 48047, United States
Digestive Health Specialists

Dothan, Alabama, 36305, United States
I.H.S Health Northwell Health

Kissimmee, Florida, 34741, United States
Institut des MICI, Clinique Ambroise Paré

Neuilly-sur-Seine, 92200, France
Medical Research Center of Connecticut, LLC

Hamden, Connecticut, 06518, United States
Twoja Przychodnia-Szczecinskie Centrum Medyczne

Szczecin, 71-434, Poland
WIP Warsaw IBD Point Profesor Kierkus

Warsaw, 00-728, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.